XML 92 R53.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Collaboration and License Agreements - Schedule of Significant Changes in Deferred Revenue Balances, IO Collaboration (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Disaggregation of Revenue [Line Items]      
Revenue recognized that was included in deferred revenue at the beginning of the period $ (294.0) $ 194.5 $ 113.1
Sanofi Collaboration Agreement, Immuno-oncology      
Disaggregation of Revenue [Line Items]      
Revenue recognized that was added to deferred revenue during the period (48.4)    
Accounting Standards Update 2014-09 | Sanofi Collaboration Agreement, Immuno-oncology      
Disaggregation of Revenue [Line Items]      
Revenue recognized that was included in deferred revenue at the beginning of the period (92.7)    
Amended IO Discovery Agreement | Sanofi Collaboration Agreement, Immuno-oncology      
Disaggregation of Revenue [Line Items]      
Increase as a result of payment received from Sanofi in connection with the termination of the 2015 IO Discovery Agreement $ 415.9 $ 135.0